219 related articles for article (PubMed ID: 36168002)
1. Chemistry Manufacturing and Controls Development, Industry Reflections on Manufacture, and Supply of Pandemic Therapies and Vaccines.
Popkin ME; Goese M; Wilkinson D; Finnie S; Flanagan T; Campa C; Clinch A; Teasdale A; Lennard A; Cook G; Mohan G; Osborne MD
AAPS J; 2022 Sep; 24(6):101. PubMed ID: 36168002
[TBL] [Abstract][Full Text] [Related]
2. Considerations for the chemistry, manufacturing and Controls (CMC) - quality package for COVID-19 vaccines- interim lessons learnt by the European medicines Agency (EMA).
Shivji R; Conocchia R; Korakianiti E; Jekerle V
Vaccine; 2022 Sep; 40(38):5539-5541. PubMed ID: 35779964
[TBL] [Abstract][Full Text] [Related]
3. Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.
Geraci G; Bernat J; Rodier C; Acha V; Acquah J; Beakes-Read G
Ther Innov Regul Sci; 2023 Sep; 57(5):940-951. PubMed ID: 37266868
[TBL] [Abstract][Full Text] [Related]
4. How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation.
McGoldrick M; Gastineau T; Wilkinson D; Campa C; Clercq N; Mallia-Milanes A; Germay O; Krishnan J; Van Ooij M; Thien MP; Mlynarczyk PJ; Saltus E; Juvin P; Clenet D; Basso A; Dellepiane N; Pagliusi S; de Moraes Stávale MC; Sivaramakrishnan VH; Desai S
Vaccine; 2022 Feb; 40(9):1215-1222. PubMed ID: 35180993
[TBL] [Abstract][Full Text] [Related]
5. Regulatory perspective for quality evaluation of lipid nanoparticle-based mRNA vaccines in China.
Lu J; Wei W; He W
Biologicals; 2023 Nov; 84():101700. PubMed ID: 37708679
[TBL] [Abstract][Full Text] [Related]
6. How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation.
McGoldrick M; Gastineau T; Wilkinson D; Campa C; De Clercq N; Mallia-Milanes A; Germay O; Krishnan J; Van Ooij M; Thien MP; Mlynarczyk PJ; Saltus E; Wauters F; Juvin P; Clenet D; Basso A; Dellepiane N; Pagliusi S; Collaço de Moraes Stávale M; Sivaramakrishnan VH; Desai S
Vaccine; 2022 Feb; 40(9):1223-1230. PubMed ID: 35180994
[TBL] [Abstract][Full Text] [Related]
7. Innovative medicine development.
Pimpaneau V; Voisin E
Technol Health Care; 2022; 30(2):499-503. PubMed ID: 34957973
[TBL] [Abstract][Full Text] [Related]
8. Worldwide Regulatory Reliance: Launching A Pilot on A Chemistry, Manufacturing and Control Post Approval Change for A Vaccine.
Gastineau T; Ban C; Basso A; Brehme F; Silva AL; Faure O; Le Palaire L; Persaud P; Rodriguez H
PDA J Pharm Sci Technol; 2023 Nov; ():. PubMed ID: 37973190
[TBL] [Abstract][Full Text] [Related]
9. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
10. How manufacturing won or lost the COVID-19 vaccine race.
King ML
Vaccine; 2024 Feb; 42(5):1004-1012. PubMed ID: 38228438
[TBL] [Abstract][Full Text] [Related]
11. Path Forward to Optimise Post-approval Change Management and Facilitate Continuous Supply of Medicines and Vaccines of High Quality Worldwide : Joint Position from EFPIA, IFPMA and Vaccines Europe.
Deavin A; Adam S; Ausborn S; Nielsen ASB; Cappellini S; Colmagne-Poulard I; Gastineau T; Gonzalez-Martinez A; Meillerais S; Mortazavi C
Ther Innov Regul Sci; 2023 Jan; 57(1):7-11. PubMed ID: 35917091
[TBL] [Abstract][Full Text] [Related]
12. Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report.
Pagliusi S; Hayman B; Jarrett S
Vaccine; 2021 Apr; 39(18):2479-2488. PubMed ID: 33838948
[TBL] [Abstract][Full Text] [Related]
13. Risks of emergency use authorizations for medical products during outbreak situations: a COVID-19 case study.
Badnjević A; Pokvić LG; Džemić Z; Bečić F
Biomed Eng Online; 2020 Oct; 19(1):75. PubMed ID: 33008462
[TBL] [Abstract][Full Text] [Related]
14. Clinical development and approval of COVID-19 vaccines.
Kalinke U; Barouch DH; Rizzi R; Lagkadinou E; Türeci Ö; Pather S; Neels P
Expert Rev Vaccines; 2022 May; 21(5):609-619. PubMed ID: 35157542
[TBL] [Abstract][Full Text] [Related]
15. Biosimilar development and review process in the BRICS-TM countries: Proposal for a standardized model to improve regulatory performance.
Rahalkar H; Sheppard A; Salek S
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):215-236. PubMed ID: 35078378
[TBL] [Abstract][Full Text] [Related]
16. Effects of the COVID-19 pandemic: new approaches for accelerated delivery of gene to first-in-human CMC data for recombinant proteins.
Broly H; Souquet J; Beck A
MAbs; 2023; 15(1):2220150. PubMed ID: 37278452
[TBL] [Abstract][Full Text] [Related]
17. Considerations for rapid development and licencing of conventional and platform technology veterinary vaccines.
Francis MJ
Avian Pathol; 2022 Apr; 51(2):107-112. PubMed ID: 35201912
[TBL] [Abstract][Full Text] [Related]
18. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
[TBL] [Abstract][Full Text] [Related]
19. Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
Kumar Suri R; Hayman B; Prasad SD; Makhoana M; Tippoo P
Vaccine; 2022 Jun; 40(26):3495-3505. PubMed ID: 35577632
[TBL] [Abstract][Full Text] [Related]
20. Innovative vaccine approaches-a Keystone Symposia report.
Cable J; Rappuoli R; Klemm EJ; Kang G; Mutreja A; Wright GJ; Pizza M; Castro SA; Hoffmann JP; Alter G; Carfi A; Pollard AJ; Krammer F; Gupta RK; Wagner CE; Machado V; Modjarrad K; Corey L; B Gilbert P; Dougan G; Lurie N; Bjorkman PJ; Chiu C; Nemes E; Gordon SB; Steer AC; Rudel T; Blish CA; Sandberg JT; Brennan K; Klugman KP; Stuart LM; Madhi SA; Karp CL
Ann N Y Acad Sci; 2022 May; 1511(1):59-86. PubMed ID: 35029310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
